"Fonterra, however, told Reuters that it had not yet received...

First 28 Last

Share
Profile

Follow
minimoke

2,946 Posts.

436

11/08/22

08:00

Post #: 63045671
Share

Originally posted by CarlosG: ↑

From Reuters:
“The dairy producer and rival Fonterra (FCG.NZ)have been advised by U.S.-based trade group International Dairy Foods Association (IDFA) that the FDA has sent similar letters to all firms seeking approvals to sell infant milk formula in the United States.”

From nzherald:
"The company has also subsequently been advised by the International Dairy Foods Association that equivalent letters have been sent to all pending enforcement discretion applicants, indicating that the FDA is deferring any further review at this time of all pending applications," a2 Milk said.

Nobody lied and there is no conspiracy here. IDFA advised both Fonterra and a2 about letter sent to all pending applicant. As usual all these debacles because of sh!tty communication. Also FDA did not gave details on why they deferred a2’s application, could be anything, including things not related to a2. Until we know details it’s all speculations, as usual

Expand

"Fonterra, however, told Reuters that it had not yet received any such notice from the FDA itself."

A2M Price at posting: $4.76 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 28 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $7.75		Change -0.055(0.71%)		Mkt cap ! $5.611B

Open	High	Low	Value	Volume
$7.87	$7.87	$7.71	$3.332M	429.1K

Buyers (Bids)

No.	Vol.	Price($)
15	4888	$7.74

Sellers (Offers)

Price($)	Vol.	No.
$7.75	3217	14

View Market Depth

No.	Vol.	Price($)
14	5205	7.740
17	20795	7.730
18	35577	7.720
15	19461	7.710
11	13905	7.700

Price($)	Vol.	No.
7.750	2051	14
7.760	11791	18
7.770	51153	13
7.780	23024	11
7.790	6563	8

Last trade - 12.38pm 27/06/2025 (20 minute delay)

A2M (ASX) Chart

"Fonterra, however, told Reuters that it had not yet received...

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

"Fonterra, however, told Reuters that it had not yet received...

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News